Companion Diagnostic Tests in Oncology Market Size, Share, Growth, and Industry Analysis, By Type (Protein Detection, DNA Detection), By Application (Pharmaceutical & Biotechnology Companies, Medical Device Companies, Research Institutes), Regional Insights and Forecast to 2035

Companion Diagnostic Tests in Oncology Market Overview

Global Companion Diagnostic Tests in Oncology Market size is estimated at USD 11726.21 Million in 2026 and is on track to expand to USD 29088.21 Million by 2035, advancing at a CAGR of 10.62%.

The Companion Diagnostic Tests in Oncology Market Market is expanding as precision oncology becomes a standard approach for cancer diagnosis and targeted therapy selection. More than 230 targeted oncology therapies globally rely on biomarker identification, while over 90 companion diagnostic tests have received regulatory approvals for clinical oncology applications. Nextgeneration sequencing platforms now identify 500+ genomic alterations in a single analysis, improving treatment selection accuracy. Lung cancer accounts for nearly 28% of companion diagnostic utilization, followed by breast cancer at 22%. More than 65% of newly approved oncology drugs require biomarker testing before prescription, strengthening the importance of companion diagnostic tests in oncology market adoption.

The United States represents the largest national market for companion diagnostic tests in oncology due to its advanced precision medicine ecosystem. More than 2.0 million new cancer cases are expected annually in the country, while over 70% of comprehensive cancer centers routinely integrate biomarkerguided treatment decisions. More than 1,900 certified molecular pathology laboratories perform oncologyrelated genomic testing across the nation. Approximately 45% of eligible metastatic lung cancer patients undergo nextgeneration sequencing before treatment selection, and more than 80% of FDAapproved targeted oncology medicines are supported by companion diagnostic testing, reinforcing continuous market expansion across the U.S. healthcare system.

What is Companion Diagnostic Tests in Oncology Market

Companion Diagnostic Tests in Oncology Market refers to the global industry focused on diagnostic assays that identify specific biomarkers, genetic mutations, or protein expressions to determine patient eligibility for targeted cancer therapies. These tests improve treatment precision, reduce unnecessary drug exposure, and support personalized oncology, with more than 90 approved diagnostic assays linked to 230+ targeted cancer therapies worldwide.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 68% of targeted oncology therapies require biomarker confirmation, while approximately 72% of precision medicine treatment decisions depend on companion diagnostic testing before therapy initiation.

• Major Market Restraint: Around 36% of healthcare facilities report reimbursement limitations, 31% experience laboratory infrastructure gaps, and nearly 28% encounter delayed access to advanced molecular diagnostic technologies.

• Emerging Trends: Approximately 54% of oncology laboratories are adopting nextgeneration sequencing panels, 47% utilize multiplex biomarker testing, and nearly 41% integrate artificial intelligence into molecular interpretation workflows.

• Regional Leadership: North America accounts for approximately 43% of global market activity, Europe contributes 29%, AsiaPacific represents 22%, and Middle East & Africa holds nearly 6%.

• Competitive Landscape: The leading 5 manufacturers collectively control approximately 69% of the global competitive landscape, while the remaining 31% is distributed among regional and specialized diagnostic developers.

• Market Segmentation: DNA detection contributes approximately 71% of total testing demand, protein detection represents 29%, while pharmaceutical and biotechnology companies account for nearly 58% of enduser utilization.

• Recent Development: Nearly 49% of newly introduced oncology companion diagnostics support nextgeneration sequencing, 33% focus on liquid biopsy applications, and approximately 18% target multiplex biomarker analysis.

Companion Diagnostic Tests in Oncology Market Latest Trends

The Companion Diagnostic Tests in Oncology Market Market is undergoing rapid technological transformation through biomarker expansion, genomic profiling, multiplex molecular diagnostics, and precision oncology integration. More than 65% of newly developed oncology drugs require biomarkerguided patient selection before treatment initiation. Nextgeneration sequencing panels capable of detecting over 500 cancerassociated mutations are replacing singlegene testing in major oncology centers. Liquid biopsy adoption has increased significantly, with circulating tumor DNA analysis now supporting early treatment monitoring for multiple cancer types. Approximately 75% of advanced lung cancer treatment guidelines recommend comprehensive genomic profiling before selecting targeted therapies.

Automation in molecular pathology laboratories has improved sample processing efficiency by approximately 30%, while digital pathology implementation continues to expand across cancer hospitals. Growing collaboration between pharmaceutical companies and diagnostic manufacturers has resulted in increased codevelopment programs supporting personalized medicine. Clinical laboratories increasingly integrate realtime PCR, fluorescence in situ hybridization, immunohistochemistry, and nextgeneration sequencing into comprehensive testing strategies. Expanding regulatory approvals for biomarkerguided therapies continue to strengthen the role of companion diagnostic tests in oncology market development.

How does AI influence the Companion Diagnostic Tests in Oncology Market

Artificial intelligence significantly improves companion diagnostic testing by accelerating genomic data interpretation and reducing diagnostic variability. AI algorithms analyze more than 1 million genomic data points within minutes, improving mutation detection accuracy by approximately 20%. Nearly 46% of advanced molecular pathology laboratories now employ AIassisted variant classification. Digital pathology systems using AI also enhance biomarker quantification, reduce reporting time by approximately 30%, and improve consistency across oncology diagnostic laboratories, supporting faster personalized treatment decisions.

Companion Diagnostic Tests in Oncology Market Dynamics

DRIVER

Rising demand for personalized oncology therapies.

Precision medicine has become the primary growth engine for the Companion Diagnostic Tests in Oncology Market Market. More than 230 targeted oncology therapies currently depend on biomarker identification before prescription. Approximately 68% of newly approved cancer drugs require companion diagnostic support for patient selection. Lung, breast, colorectal, melanoma, ovarian, and gastric cancers increasingly depend on molecular profiling to optimize treatment decisions. More than 18 million molecular oncology tests are performed globally each year, reflecting expanding clinical adoption. Clinical guidelines recommend genomic profiling before firstline therapy in several metastatic cancers, increasing routine testing volumes. Expansion of nextgeneration sequencing laboratories and automated molecular pathology platforms continues improving accessibility. 

RESTRAINT

Limited reimbursement and high implementation complexity.

Although companion diagnostics deliver clinical value, implementation remains restricted by reimbursement challenges and laboratory infrastructure requirements. Approximately 36% of healthcare providers report inconsistent reimbursement coverage for advanced molecular testing. More than 32% of community hospitals lack comprehensive genomic sequencing capability, requiring external laboratory referrals. Advanced sequencing platforms require specialized laboratory infrastructure, molecular pathologists, bioinformatics professionals, and quality assurance systems. Sample transportation delays can extend turnaround time beyond 10 days in certain regions. Limited awareness among healthcare professionals also affects testing utilization, particularly in developing healthcare systems.

OPPORTUNITY

Expansion of precision medicine and liquid biopsy technologies.

Growing utilization of liquid biopsy creates substantial opportunities for the Companion Diagnostic Tests in Oncology Market Market. Circulating tumor DNA analysis enables minimally invasive testing using blood samples instead of tissue biopsies. More than 250 clinical studies currently evaluate liquid biopsy applications in oncology. Approximately 44% of pharmaceutical companies include biomarkerdriven patient selection during oncology clinical trials. Expanding immunotherapy indications create additional opportunities for PDL1, MSI, TMB, and other predictive biomarker assays. Emerging biomarkers continue increasing diagnostic applications across pancreatic, ovarian, prostate, liver, and gastric cancers. National precision medicine initiatives across multiple countries also support investments in genomic infrastructure, increasing longterm demand for companion diagnostic platforms and integrated molecular testing services.

CHALLENGE

Standardization of biomarker testing across laboratories.

Laboratory standardization remains one of the major challenges affecting market development. Different sequencing platforms, testing methodologies, bioinformatics pipelines, and interpretation standards can produce variable clinical results. Approximately 27% of laboratories report challenges related to variant interpretation consistency. Quality assurance programs require frequent proficiency testing and validation to maintain diagnostic accuracy. Biomarker discovery progresses faster than clinical validation, creating uncertainty regarding implementation timelines. Data storage requirements continue expanding because comprehensive genomic sequencing generates terabytes of patient information annually. 

Why is the Companion Diagnostic Tests in Oncology Market Industry experiencing rapid growth

The Companion Diagnostic Tests in Oncology Market industry is experiencing rapid growth because precision medicine has become a central component of modern cancer care. More than 230 targeted oncology therapies now depend on biomarker identification before treatment selection, while over 90 approved companion diagnostic assays are used globally in clinical practice. Approximately 72% of advanced nonsmall cell lung cancer patients are recommended to undergo comprehensive biomarker testing before firstline therapy. The increasing prevalence of cancer, with over 20 million new cancer cases diagnosed annually worldwide, continues to expand demand for molecular diagnostics. Nextgeneration sequencing platforms can simultaneously analyze over 500 genomic variants, reducing testing time by nearly 35% compared with sequential singlegene testing.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Companion Diagnostic Tests in Oncology Market Market is segmented by type into Protein Detection and DNA Detection, while applications include Pharmaceutical & Biotechnology Companies, Medical Device Companies, and Research Institutes. DNA Detection represents the leading technology with approximately 71% market share because of its broad use in identifying actionable genomic mutations such as EGFR, KRAS, ALK, and BRCA. Protein Detection contributes nearly 29% through immunohistochemistry and related biomarker assays. By application, Pharmaceutical & Biotechnology Companies account for approximately 58% of market demand, Medical Device Companies contribute 24%, and Research Institutes represent 18%, supported by increasing oncology research, biomarker validation programs, and precision medicine initiatives.

By Type

Protein Detection

Protein Detection accounts for approximately 29% of the Companion Diagnostic Tests in Oncology Market Market. The segment remains essential for evaluating protein expression biomarkers including PDL1, HER2, and hormone receptors that directly influence treatment selection in breast, lung, gastric, and urothelial cancers. Immunohistochemistry remains the dominant technology within this segment because of its standardized laboratory workflows and broad clinical acceptance. More than 80% of breast cancer patients undergo HER2 protein testing before targeted therapy decisions. PDL1 testing is now recommended for multiple immunotherapy indications, supporting increased testing volumes worldwide. Continuous improvements in automated staining systems, digital pathology, and AIassisted image analysis have enhanced diagnostic consistency by approximately 25%, strengthening the clinical importance of proteinbased companion diagnostics.

DNA Detection

DNA Detection dominates the Companion Diagnostic Tests in Oncology Market Market with approximately 71% market share. The segment benefits from extensive use of polymerase chain reaction, nextgeneration sequencing, fluorescence in situ hybridization, and digital PCR technologies. More than 500 genomic alterations can be analyzed simultaneously using advanced sequencing platforms, enabling comprehensive molecular profiling for precision oncology. DNA detection is routinely used to identify EGFR, KRAS, ALK, ROS1, BRAF, BRCA1, BRCA2, RET, MET, and NTRK alterations across multiple cancer types. Approximately 75% of metastatic nonsmall cell lung cancer treatment pathways require genomic mutation testing before targeted therapy selection. Increasing adoption of liquid biopsy, reduced sequencing turnaround time, and improved bioinformatics continue strengthening the leadership position of the DNA Detection segment.

By Application

Pharmaceutical & Biotechnology Companies

Pharmaceutical & Biotechnology Companies represent the largest application segment, accounting for approximately 58% of the Companion Diagnostic Tests in Oncology Market Market. Companion diagnostics have become an essential component of oncology drug development because regulatory agencies increasingly encourage simultaneous approval of targeted therapies and associated diagnostic assays. More than 65% of oncology drug candidates currently incorporate biomarkerdriven patient selection during clinical development. Pharmaceutical organizations collaborate extensively with molecular diagnostic developers to validate predictive biomarkers and optimize clinical trial enrollment. Biomarkerguided studies improve treatment response rates while reducing unnecessary exposure to ineffective therapies.

Medical Device Companies

Medical Device Companies contribute approximately 24% of the Companion Diagnostic Tests in Oncology Market Market. These organizations develop automated diagnostic instruments, molecular analyzers, digital pathology platforms, sequencing systems, and laboratory automation technologies supporting companion diagnostic workflows. Modern sequencing instruments can process more than 1,000 patient samples per week in highvolume laboratories. Digital pathology systems reduce reporting variability by approximately 20%, while integrated laboratory automation improves sample processing efficiency by nearly 30%. Growing demand for standardized molecular testing and regulatorycompliant laboratory solutions continues creating opportunities for medical device manufacturers across global healthcare systems.

Which segment is expected to witness the fastest growth

The DNA Detection segment is expected to witness the fastest growth, with an estimated market share of approximately 71% and continued expansion driven by comprehensive genomic profiling, nextgeneration sequencing, liquid biopsy adoption, and increasing approvals of biomarkertargeted oncology therapies. The growing use of multigene panels capable of analyzing over 500 genomic alterations further strengthens the segment's longterm growth potential.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Companion Diagnostic Tests in Oncology Market Regional Outlook

The Companion Diagnostic Tests in Oncology Market Market demonstrates strong regional variation based on healthcare infrastructure, precision medicine adoption, regulatory approvals, and molecular diagnostic capacity. North America leads with approximately 43% market share owing to widespread biomarker testing and targeted therapy availability. Europe contributes nearly 29%, supported by expanding genomic medicine initiatives. AsiaPacific accounts for around 22%, benefiting from increasing cancer incidence and investments in molecular diagnostics. Middle East & Africa represents approximately 6%, where improving healthcare infrastructure and precision oncology programs are gradually increasing adoption of companion diagnostic technologies.

North America

North America dominates the Companion Diagnostic Tests in Oncology Market Market with an estimated 43% market share. The region benefits from advanced molecular diagnostic infrastructure, widespread adoption of precision oncology, and strong integration of biomarker testing into cancer treatment guidelines. The United States performs millions of molecular oncology tests annually through more than 1,900 certified molecular laboratories. Over 80% of newly approved targeted oncology medicines in the region are supported by companion diagnostic assays. Lung, breast, colorectal, melanoma, and ovarian cancers remain the leading indications for genomic profiling. Approximately 75% of comprehensive cancer centers routinely perform nextgeneration sequencing before selecting targeted treatments for advanced cancers.

Europe

Europe accounts for approximately 29% of the Companion Diagnostic Tests in Oncology Market Market and remains one of the most advanced regions for precision oncology implementation. More than 450 specialized molecular pathology laboratories across major European countries perform companion diagnostic testing for targeted cancer therapies. Germany, France, the United Kingdom, Italy, and Spain collectively represent over 70% of regional testing activity. National cancer control strategies increasingly emphasize genomic profiling before therapy selection, particularly for lung, breast, colorectal, ovarian, and melanoma patients. More than 60% of tertiary oncology hospitals routinely perform biomarker testing using polymerase chain reaction, immunohistochemistry, fluorescence in situ hybridization, and nextgeneration sequencing platforms. Clinical guidelines across Europe recommend comprehensive genomic profiling for multiple advanced cancers, supporting wider adoption of companion diagnostic technologies.

AsiaPacific

AsiaPacific holds approximately 22% of the Companion Diagnostic Tests in Oncology Market Market and represents the fastestexpanding regional landscape because of increasing cancer incidence, expanding healthcare infrastructure, and rising investments in molecular diagnostics. China, Japan, South Korea, India, and Australia collectively account for more than 85% of regional companion diagnostic activity. China has significantly expanded genomic sequencing capacity, with more than 700 advanced molecular laboratories supporting oncology testing. Japan remains a leader in precision oncology implementation, where national reimbursement policies support comprehensive genomic profiling for selected cancer indications. More than 55% of tertiary cancer hospitals across developed AsiaPacific countries routinely integrate biomarker testing into treatment planning.The region also experiences rapid growth in pharmaceutical research and clinical trials focused on targeted therapies.

Middle East & Africa

The Middle East & Africa accounts for approximately 6% of the Companion Diagnostic Tests in Oncology Market Market but demonstrates gradual expansion as precision oncology services become more accessible. Countries including Saudi Arabia, the United Arab Emirates, South Africa, Qatar, and Egypt are investing in advanced molecular pathology laboratories and genomic medicine programs. More than 120 specialized oncology centers across the region now provide biomarker testing for targeted cancer therapies. National cancer strategies increasingly recommend genomic profiling for selected metastatic cancers, particularly lung and breast cancer. Large tertiary hospitals continue adopting nextgeneration sequencing systems and automated molecular diagnostic platforms to improve patient care.International collaborations with global pharmaceutical companies and research organizations are accelerating technology transfer and laboratory development. 

List of Top Companion Diagnostic Tests in Oncology Market Companies

• Genomic Health
• QIAGEN
• Agilent
• Agendia
• BioMerieux
• Illumina
• Siemens Healthcare
• Thermo Fisher

List of Top tow Companies Market Share

• Roche – Approximately 28% market share, supported by an extensive portfolio of oncology companion diagnostics, broad collaborations with pharmaceutical companies, and leadership in molecular diagnostics, immunohistochemistry, PCR, and nextgeneration sequencing technologies. The company maintains one of the largest global installed bases of oncology diagnostic systems.

• Abbott – Approximately 16% market share, driven by advanced molecular diagnostic platforms, realtime PCR technologies, and a strong global presence in precision oncology testing. Abbott continues expanding biomarkerbased diagnostic capabilities through innovation, regulatory approvals, and partnerships supporting personalized cancer treatment.

Investment Analysis and Opportunities

Investment activity in the Companion Diagnostic Tests in Oncology Market Market continues to accelerate as pharmaceutical manufacturers, molecular diagnostic companies, and healthcare providers prioritize precision medicine. More than 65% of oncology drug development programs now incorporate biomarkerdriven patient selection, increasing demand for companion diagnostic codevelopment. Over 250 active clinical studies globally are evaluating new predictive biomarkers for targeted cancer therapies. Investment in nextgeneration sequencing infrastructure has expanded substantially, with highthroughput sequencing systems capable of processing more than 1,000 patient samples weekly. Digital pathology, artificial intelligence, and cloudbased genomic analytics have become major investment priorities because they improve interpretation accuracy and reduce reporting time by approximately 30%.

Significant opportunities also exist in liquid biopsy technologies, where circulating tumor DNA testing is increasingly used for treatment monitoring, resistance mutation detection, and minimal residual disease assessment. More than 40 oncology indications are currently under evaluation for expanded biomarkerguided therapeutic approaches. Emerging markets continue investing in molecular pathology laboratories, automated sample processing, and genomic databases to strengthen national precision medicine capabilities. Strategic collaborations between pharmaceutical companies and diagnostic developers continue increasing codevelopment agreements for targeted therapies. Expansion of multiplex assays capable of detecting hundreds of genomic alterations within a single test further enhances investment attractiveness.

New Product Development

New product development in the Companion Diagnostic Tests in Oncology Market Market focuses on increasing analytical accuracy, expanding biomarker coverage, and improving laboratory efficiency. Modern nextgeneration sequencing assays can evaluate more than 500 genomic alterations from a single patient sample, enabling comprehensive molecular profiling across multiple tumor types. Manufacturers are introducing multiplex companion diagnostic panels capable of simultaneously detecting EGFR, KRAS, BRAF, ALK, ROS1, RET, MET, HER2, BRCA, and NTRK biomarkers. These advanced panels reduce diagnostic turnaround time by approximately 35% while improving workflow efficiency in highvolume oncology laboratories.

Liquid biopsy innovation has become another major development area, allowing noninvasive bloodbased testing for mutation detection and treatment monitoring. Artificial intelligence is increasingly integrated into variant interpretation software, reducing manual analysis time by nearly 25% while improving consistency across laboratories. Digital pathology platforms continue evolving with automated biomarker quantification and image analysis capabilities. Manufacturers are also developing companion diagnostics specifically for immunotherapy biomarkers, including PDL1 expression, tumor mutational burden, microsatellite instability, and homologous recombination deficiency. Miniaturized sequencing platforms, cloudbased genomic reporting systems, and automated laboratory instruments further enhance scalability and accessibility.

Five Recent Developments (20232025)

• August 2023: QIAGEN received FDA approval for the therascreen PDGFRA RGQ PCR Kit as a companion diagnostic for AYVAKIT in gastrointestinal stromal tumors. The assay identifies the PDGFRA D842V mutation from formalinfixed tumor tissue and provides validated results through the RotorGene Q MDx platform, expanding biomarkerguided treatment access for a clinically defined GIST population.
• October 2023: Thermo Fisher Scientific signed a companion diagnostic agreement with Boehringer Ingelheim to develop an NGSbased test for selecting nonsmall cell lung cancer patients for targeted treatment. The collaboration uses the Oncomine Dx Target Test platform, which supports multiple actionable biomarkers and is commercially approved across more than 15 countries, extending precision oncology testing capabilities.
• March 2024: Bayer and Thermo Fisher Scientific announced a collaboration to increase access to precision cancer medicines through nextgeneration sequencing companion diagnostics. The program utilizes Thermo Fisher’s Oncomine platform to identify actionable alterations from limited tumor specimens. The platform supports 11 approved companion diagnostic biomarkers, 16 pharmaceutical partners, and coverage across 20 countries, strengthening decentralized oncology testing.
• October 2024: Thermo Fisher Scientific received FDA approval for an NGSbased companion diagnostic supporting the first targeted therapy for Grade 2 IDHmutant glioma. The expanded Oncomine Dx Target Test indication enables detection of IDH1 and IDH2 alterations from tumor tissue, adding brain cancer to the platform’s precision oncology applications and supporting treatment selection through standardized genomic profiling.
• January 2025: Roche received FDA approval for the PATHWAY HER2 4B5 test as the first companion diagnostic identifying HER2ultralow metastatic breast cancer patients eligible for ENHERTU. The assay expanded HER2 classification beyond positive, low, and negative categories, enabling pathologists to assess previously underserved patients and supporting more precise treatment selection in metastatic breast cancer.

Report Coverage of Companion Diagnostic Tests in Oncology Market

The Companion Diagnostic Tests in Oncology Market Market report evaluates the industry across 2 principal test types, 3 major application categories, and 4 geographic regions. The type analysis covers Protein Detection and DNA Detection, with DNA Detection accounting for approximately 71% of market activity and Protein Detection representing nearly 29%. Application coverage includes Pharmaceutical & Biotechnology Companies with approximately 58% share, Medical Device Companies with 24%, and Research Institutes with 18%.Regional assessment examines North America, Europe, AsiaPacific, and Middle East & Africa. North America contributes approximately 43% of global market activity, followed by Europe at 29%, AsiaPacific at 22%, and Middle East & Africa at 6%. The Companion Diagnostic Tests in Oncology Market Market Report analyzes more than 10 major manufacturers, including Roche, Abbott, QIAGEN, Agilent, Illumina, Thermo Fisher, BioMerieux, Siemens Healthcare, Agendia, and Genomic Health.

The report covers PCR, nextgeneration sequencing, immunohistochemistry, fluorescence in situ hybridization, digital PCR, liquid biopsy, and artificial intelligenceassisted interpretation. It evaluates more than 500 detectable genomic alterations, over 90 approved oncology companion diagnostic assays, and biomarker applications involving EGFR, ALK, ROS1, KRAS, BRAF, HER2, PDL1, BRCA, RET, MET, NTRK, IDH, and CLDN18.2. The coverage also includes market drivers, restraints, opportunities, challenges, investment activity, product innovation, competitive positioning, regulatory approvals, clinical adoption, testing infrastructure, and manufacturer developments recorded between 2023 and 2025.

Companion Diagnostic Tests in Oncology Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 11726.21 Billion in 2026
Market Size Value By	USD 29088.21 Billion by 2035
Growth Rate	CAGR of 10.62% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Protein Detection DNA Detection By Application : Pharmaceutical & Biotechnology Companies Medical Device Companies Research Institutes
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample